Cargando…

Landmark Cancer Clinical Trials and Real-World Patient Populations: Examining Race and Age Reporting

SIMPLE SUMMARY: Food and Drug Administration (FDA) drug approvals from July 2007 to June 2019 were reviewed to identify oncology approvals, and trials with age details were reviewed for the study. We hypothesized that the clinical trials that do not report race are likely to suffer from a higher deg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jayakrishnan, Thejus, Aulakh, Sonikpreet, Baksh, Mizba, Nguyen, Kianna, Ailawadhi, Meghna, Samreen, Ayesha, Parrondo, Ricardo, Sher, Taimur, Roy, Vivek, Manochakian, Rami, Paulus, Aneel, Chanan-Khan, Asher, Ailawadhi, Sikander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616211/ https://www.ncbi.nlm.nih.gov/pubmed/34830924 http://dx.doi.org/10.3390/cancers13225770

Ejemplares similares

The digital divide: Racial disparities in adoption and utilization of health information technology among patients with lymphoid cancers
por: Ailawadhi, Sikander, et al.
Publicado: (2023)

Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia
por: Kumar, Vivek, et al.
Publicado: (2019)

Management of lytic bone disease in lymphoplasmacytic lymphoma: A case report and review of the literature
por: Baksh, Mizba, et al.
Publicado: (2021)

Myelomatous ascites and pleural effusion in relapsed multiple myeloma
por: Baksh, Mizba, et al.
Publicado: (2022)

Retreatment with obinutuzumab: An addition to the therapeutic landscape of chronic lymphocytic leukemia
por: Khurana, Sharad, et al.
Publicado: (2019)

A Panel Evaluation of the Changes in the General Public’s Social-Media-Following of United States’ Public Health Departments during COVID-19 Pandemic
por: Khokhar, Areej, et al.
Publicado: (2021)

Use of KRD-PACE as Salvage Therapy in Aggressive, Relapsed/Bortezomib-Refractory Extramedullary Multiple Myeloma: A Report of Two Cases and Literature Review
por: Parrondo, Ricardo D., et al.
Publicado: (2020)

Updates in the Use of BCL-2-Family Small Molecule Inhibitors for the Treatment of Relapsed/Refractory Multiple Myeloma
por: Parrondo, Ricardo D., et al.
Publicado: (2022)

RETRACTED ARTICLE: Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis
por: Parrondo, Ricardo D., et al.
Publicado: (2022)

Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety
por: Das, Saurav, et al.
Publicado: (2023)

AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma
por: Ailawadhi, Sikander, et al.
Publicado: (2023)

Immunophenotyping of Waldenströms Macroglobulinemia Cell Lines Reveals Distinct Patterns of Surface Antigen Expression: Potential Biological and Therapeutic Implications
por: Paulus, Aneel, et al.
Publicado: (2015)

Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy
por: Longcor, Jarrod, et al.
Publicado: (2022)

Association of Race, Socioeconomic Factors, and Treatment Characteristics With Overall Survival in Patients With Limited-Stage Small Cell Lung Cancer
por: Zhou, Kexun, et al.
Publicado: (2021)

Targeted treatment for chronic lymphocytic leukemia
por: Masood, Aisha, et al.
Publicado: (2011)

Trends in participant race and sex reporting in lung cancer phase III clinical trials
por: Aslam, Faaiq N., et al.
Publicado: (2023)

Trends in utilization of stored cryopreserved autologous peripheral hematopoietic cells intended for a second (or beyond) autologous hematopoietic cell transplantation in patients with multiple myeloma: a single center experience
por: Yassine, Farah, et al.
Publicado: (2023)

Survival of Black and White Patients With Stage IV Small Cell Lung Cancer
por: Shi, Huashan, et al.
Publicado: (2021)

Second primary acute lymphoblastic leukemia in adults: a SEER analysis of incidence and outcomes
por: Swaika, Abhisek, et al.
Publicado: (2017)

Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER‐medicare analysis
por: Ailawadhi, Sikander, et al.
Publicado: (2017)

Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups
por: Ailawadhi, S, et al.
Publicado: (2014)

Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
por: Hampel, Paul J., et al.
Publicado: (2022)

Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma
por: Bansal, Radhika, et al.
Publicado: (2023)

Prevention Of Skeletal Related Events In Multiple Myeloma: Focus On The RANK-L Pathway In The Treatment Of Multiple Myeloma
por: Parrondo, Ricardo D, et al.
Publicado: (2019)

Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma
por: Ailawadhi, Sikander, et al.
Publicado: (2018)

Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics
por: Razavi, P, et al.
Publicado: (2013)

Survival trends among non‐small‐cell lung cancer patients over a decade: impact of initial therapy at academic centers
por: Lou, Yanyan, et al.
Publicado: (2018)

Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma
por: Parrondo, Ricardo D., et al.
Publicado: (2022)

Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome: A systematic review and meta-analysis
por: Aulakh, Sonikpreet, et al.
Publicado: (2020)

Nimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenströms macroglobulinemia
por: Chitta, K, et al.
Publicado: (2014)

Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials
por: Ailawadhi, Sikander, et al.
Publicado: (2018)

Distribution of clonal hematopoiesis of indeterminate potential (CHIP) is not associated with race in patients with plasma cell neoplasms
por: Gagnon, Marie-France, et al.
Publicado: (2022)

Feasibility of a clinically integrated rehabilitation therapist in a Neuro-Oncology clinic
por: Stout, Nicole L, et al.
Publicado: (2023)

Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment
por: Paulus, A, et al.
Publicado: (2017)

A Systematic Review of Cases of Acute Respiratory Distress Syndrome in the Coronavirus Disease 2019 Pandemic
por: Baksh, Mizba, et al.
Publicado: (2020)

Duration of frontline therapy and impact on clinical outcomes in newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant
por: Ailawadhi, Sikander, et al.
Publicado: (2022)

Genomic landscape of lung adenocarcinomas in different races
por: Shi, Huashan, et al.
Publicado: (2022)

The Functional Status of Patients with AIDS Attending Antiretroviral Treatment Center
por: Thejus, TJ, et al.
Publicado: (2009)

Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance
por: Ho, Matthew, et al.
Publicado: (2022)

Second symptomatic COVID-19 infections in patients with an underlying monoclonal gammopathy
por: Zanwar, Saurabh, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5sls8di612eospgtq0a3a5c60k